<DOC>
	<DOCNO>NCT01493713</DOCNO>
	<brief_summary>The purpose study evaluate correlation overall objective response accord RECIST v1.1 . criterion evaluate conventional imaging technique , morphologic response CT , histopathologic response patient resectable hepatic metastasis secondary colorectal cancer treat bevacizumab combination XELOX .</brief_summary>
	<brief_title>Correlation Between RECIST , Morphologic Response CT- Histopathologic Response Hepatic Metastasis Secondary Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Written informed consent . 2 . Age ≥ 18 year . 3 . ECOG 01 . 4 . Life expectancy least 12 week . 5 . Histologic confirmation adenocarcinoma colon rectum , accord 7th edition TNM classification , evidence liver metastasis accord RECIST v 1.1 criterion ( Annex V ) . Patients diagnosis liver metastasis present synchronically diseasefree interval . The primary tumor shall resect previously although inverse approach may acceptable tumor symptomatic . Patients combine surgery primary tumor metastasis plan eligible . 6 . Availability tumor sample KRAS gene determination . 7 . No prior chemotherapy treatment metastatic CRC . 8 . Patients resectable hepatic metastasis colorectal carcinoma satisfy follow criterion : ≤ 4 metastasis Size &lt; 10 cm Technically feasible R0 resection , residual liver volume le 30 % NOTE : Patients bilateral metastasis may enrol satisfy criterion ( &lt; 4 metastasis size &lt; 10 cm ) . 9 . Adequate bone marrow , liver kidney function , define : Hemoglobin ≥ 9.0 g/dl ( transfusion give treatment ) . Platelet count ≥ 100 × 109/L . Absolute neutrophil count ( ANC ) ≥ 1.5 × 109/L . Serum bilirubin ≤ 1.5 time high upper limit normality ( ULN ) . Alkaline phosphatase , ALT ( SGPT ) AST ( SGOT ) ≤ 5 × ULN . Serum creatinine &lt; 1.5 x ULN creatinine clearance ≥ 50 ml/min accord Cockcroft Gault formula ( Annex VII ) . INR &lt; 1.5 within 7 day prior start study treatment . aPTT &lt; 1.5 × ULN within 7 day prior start study treatment . Exception : Patients treat complete dos anticoagulant due venous thromboembolism usually must INR value within establish range ( usually 23 ) . The patient must receive stable dose anticoagulant treatment enrollment study . Urine strip proteinuria &lt; 2+ . If result reactive strip urine ≥ 2+ , 24hour urine sample must demonstrate ≤ 1 g protein 24 hour order include patient . 10 . Women childbearing potential must negative pregnancy test serum urine 7day period enter study . Postmenopausal woman must amenorrheic least 12 month . Likewise , men woman participate study must use effective contraceptive method ( e.g. , abstinence , intrauterine device , oral contraceptive , double barrier method surgical sterility ) , begin upon sign informed consent form least 6 month end treatment last dose , whichever occur first . 11 . The subject must capacity , opinion investigator , comply procedure examination study followup . 1 . Patients nonresectable hepatic metastasis time enrollment . 2 . Previous systemic local treatment metastatic disease . 3 . Presence metastatic extrahepatic disease . 4 . Neoadjuvant adjuvant chemotherapy/radiotherapy 6 month prior enter study . 5 . Use investigational drug 4 week start study treatment . 6 . Current recent ( 10 day prior first administration study treatment ) use acetylsalicylic acid ( &gt; 325 mg/day ) clopidogrel ( 75 mg/day ) . 7 . Current presence peripheral neuropathy = 1 ( CTCAE ) . 8 . Hypertension properly control ( define systolic pressure &gt; 150 mm Hg and/or diastolic pressure &gt; 100 mm Hg repeat measurement ) , despite optimal medical management . 9 . Previous history hypertensive episode hypertensive encephalopathy . 10 . CHF class II high NYHA classification . 11 . History myocardial infarction unstable angina within 6 month prior start study treatment . 12 . Significant vascular disease ( e.g. , aortic aneurysm require surgery , pulmonary embolism recent peripheral arterial thrombosis ) 6 month prior start study treatment . 13 . History hemoptysis ( equivalent = ½ teaspoon redcolored blood per episode ) month prior study treatment . 14 . Major surgery , open surgical biopsy significant trauma 4 week prior start study treatment . Thickneedle biopsy major organ 7 day prior enter study . Insertion vascular access &gt; 3 day enter study allow . 15 . Tests history significant hemorrhagic diathesis coagulation disorder ( absence anticoagulation ) . 16 . History abdominal fistula gastrointestinal perforation 6 month prior start study treatment . 17 . Intraabdominal acute inflammatory process . 18 . Serious unhealed wound , active ulcer untreated bone fracture . 19 . History another neoplastic disease aside colorectal cancer last 2 year prior start study treatment , exception basal cell squamous cell carcinoma skin carcinoma situ cervix treat curatively . 20 . Human immunodeficiency virus infection chronic infection hepatitis B C virus presence uncontrolled intercurrent infection , severe uncontrolled concomitant disease . 21 . Current grade ≥ 2 infection ( CTCAE ) . 22 . Pregnant breastfeed woman . 23 . Known allergy , suspicion allergy , hypersensitivity study drug ( bevacizumab , oxaliplatin , capecitabine ) and/or iodide contrast agent . 24 . Incapacity oral intake . 25 . Any important uncontrolled medical , psychological , psychiatric social problem interfere subject 's participation study evaluation study result represent increased risk complication related patient 's treatment . 26 . Patients combine surgery primary tumor metastasis plan eligible . 27 . Venous Cava invasion 2 hepatic venous invasion Both portal venous invasion Remanent future minor 40 % Use portal embolization previous hepatectomy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>